eavesdropping in houston

Overheard: Energy transition experts weigh in at Houston climatetech conference

Greentown Labs hosted its Climatetech Summit from both its Houston location and its Boston-area office. Photo via greentownlabs.com

This week, world leaders are discussing climate change and the future of our planet at the United Nations Climate Change Conference, also known as COP26, but local leaders were also discussing much closer to home.

Greentown Labs hosted its Climatetech Summit on Thursday, November 4, at both its offices in Houston and Sommerville, Massachusetts. The hybrid event featured a full day of networking, panels, and thought leadership.

Missed the conversation? Here are five key moments from the event.

​"Houston cannot transition without transitioning its workforce, and we need to help with that and make sure that people understand that. Demystifying the jobs of the future is key."

— says Juliana Garaizar, Greentown Labs' head of Houston incubator and vice president of innovation, in her welcome address.

"The energy transition in Houston needs to happen in an equitable way," she says. "Houston is the most diverse city in the US. It is up to us now to make it the most inclusive."

"The world will continue to need a lot of hydrocarbons for quite a long period of time, and Houston can and should remain a leader there. But it will not be an engine for growth."

— says Bobby Tudor, former chair of the Greater Houston Partnership and chairman of Tudor, Pickering, Holt & Co, in his keynote.

"If we are not going to have that business, which accounts for approximately 40 percent of all jobs in Greater Houston, be an engine of growth, we sure as heck better find businesses that are, or we will not have the same kind of prosperity that we've had in our region," Tudor says.

"The Energy Capital of the World will be the leader in the global energy transition."

— says Mayor Sylvester Turner in his address.

"As a lifelong Houston, I am proud of our history and proud of the innovation, growth, and prosperity the energy industry brings to our community," he continues. "But, as leaders of the energy industry, I believe it is our responsibility to continue this legacy and develop the innovative technologies and practices needed to decarbonize the entire energy sector worldwide."

"Texas has more potential to produce clean energy — wind, solar, storage — and efficiency than any other state."

saysHARC President + CEO John Hall in his address.

"And we're fortunate that today — even though we continue to lead the country in producing oil and gas — 40 percent of the electricity being used in this state is zero emitting."

"You don't get change by wishing and hoping. You need to plan and to act."

says Quantum New Energy CEO Patricia Vega on the panel about transitioning the workforce.

"We live in a world where we can track steps, calories, and likes on social media, but if I ask each one of you what is your carbon footprint or carbon efficiency, many of us don't know how to answer those questions and don't have the tools," she adds.

Trending News

Building Houston

 
 

This month, TMCi is welcoming a slew of health tech and cancer innovators who will advance solutions in medicine over the next several months. Image via TMC.edu

The Texas Medical Center has announced the latest cohorts of its two health tech accelerators.

The Texas Medical Center Innovation has named eight companies that are in the Spring 2023 Accelerator for HealthTech cohort. TMCi also announced 21 participants are set to join the 2023 Accelerator for Cancer Therapeutics cohort. Both programs connect the entrepreneurs and innovators to experts at TMC’s campuses to solve unmet clinical needs and reach the next business milestone.

“At TMC Innovation, we start with a promise of uniting cutting-edge innovators in science and medicine with the talent found at the Texas Medical Center," says Emily Reiser, associate director of TMC Innovation, in a news release. "Our 2023 cohort members are tackling some of the most critical issues we face today in healthcare.

"We are excited to welcome a new group of researchers and companies to the TMC Innovation Factory, and to work collaboratively with our new cohort members and our partners from across the Texas Medical Center," she continues.

Here's what 2023 can expect from these two program's cohorts.

TMCi HealthTech Accelerator

The six-month, twice annual HealthTech Accelerator — originally launched in 2014 with over 225 alumni companies — focuses on digital health and medical device startups. The spring cohort are addressing solutions across maternal medicine, mental health, diagnostics, patient experience, and artificial intelligence.

"Uniting talented professionals from across the globe provides a unique opportunity for innovation, creativity, and development in diverse areas of expertise," says Devin Dunn, head of the Accelerator for Healthtech at TMCi, in the release. "Our tailored program maximizes participants' experiences while determining the best match between these companies and Texas Medical Center’s network."

The cohort was selected following a November bootcamp that introduced potential startup members to the TMC and the Houston health care community.

The following companies will join the TMC this month:

  • Based in Roseville, Minneapolis, Bloom Standard is deploying the first self-driving pediatric ultrasound to earlier diagnose heart and lung conditions in primary care, remote and under-resourced settings.
  • San Francisco-based Ejenta automates remote monitoring and care using AI technology exclusively licensed from NASA. “Intelligent agents” learn from connected devices, claims and EMR data to monitor patients, predict health and to provide automated support for patients and automated workflow for clinicians.
  • Kintsugi, based in Berkley, California, is on a mission to see mental health more clearly by developing novel voice biomarker infrastructure to detect signs of depression and anxiety from short clips of free-form speech.
  • San Francisco-based Lana Health is modernizing patient experiences, across the care continuum with an end-to-end, scalable platform, enabling frictionless care transitions, high patient satisfaction, and better clinical outcomes.
  • Liberate Medical, from Crestwood, Kentucky, improves outcomes for mechanically ventilated patients using its breakthrough, non-invasive, respiratory muscle-protective, neurostimulation device, VentFree.
  • Limbix, headquartered in Palo Alto, has a mission to improve mental health with accessible technology.
  • Nua Surgical, from Galway, Ireland, Nua Surgical is an award-winning Irish start-up dedicated to innovating in women’s health.
  • Houston-based Prana Thoracic is developing solutions for the detection and intervention of early-stage lung cancer.

Accelerator for Cancer Therapeutics

The TMC has announced the 21 researchers and companies tapped to join the 2023 Accelerator for Cancer Therapeutics.

The nine-month program, funded by the Cancer Prevention and Research Institute of Texas in partnership with the Gulf Coast Consortia and the University of Texas Medical Branch, supports investigators and early-stage biotechnology companies with innovative solutions in cancer therapeutics. Participants will be mentored by a group of scientific, business, and innovation leaders to ultimately be positioned to apply for grants and pitch to investors and corporate partners to further the development of their innovative cancer solutions.

“For this third cohort, we focused on a strategic and extensive recruitment process, including the evaluation of 1,679 cancer research projects. From 56 applications, we selected 21 participants that will gain access to valuable resources, integrated training and mentorship to prepare for clinical trials,” says Ahmed AlRawi, program manager of Accelerator for Cancer Therapeutics, in the release. “Our 2023 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. We are excited to continue the momentum and build off the successes of our previous years.”

Forty-five participants have gone through the accelerator program since its launch in 2021, and collectively, the entrepreneurs have raised more than $90 million in funding and three projects are in the clinic.

The 2023 cohort participants are focused on a wide range of therapeutic assets, including small molecule, antibody, peptide/protein, cell therapy, and other. The 2023 cohort kicks off their nine-month program in January.

The participants include:

  1. Dr. Amit K. Tripathi – UNT-Health Science Center
  2. Dr. Darshan Gandhi (ImproveBio, LLC)
  3. Dr. Frank McKeon (Tract Pharmaceutical) – University of Houston
  4. Dr. Hemanta Baruah (Aakha Biologics)
  5. Dr. Joshua Gruber – UT-Southwestern
  6. Dr. Kyoji Tsuchikama – UT Health Science Center-Houston
  7. Dr. Maralice Conacci Sorrell – UT-Southwestern
  8. Dr. Michael Buszczak – UT-Southwestern
  9. Dr. Nadezhda (Nadia) German -Texas Tech-Lubbock
  10. Dr. Parsa Modareszadeh (HemePro Therapeutics) – UT-Dallas
  11. Dr. Robert Kruse (HydroGene Therapeutics)
  12. Dr. Xiang Zhang – Baylor College of Medicine
  13. Dr. Youngwook Won (Singular Immune, Inc.)
  14. Dr. Zhi-Ping Liu (Raphael Pharmaceutical LLC) – UT-Southwestern
  15. Dr. Jonathan Arambula (InnovoTEX Inc.)
  16. Dr. Isaac Chan – UT-Southwestern
  17. Dr. Olga Granaturova (Ruptakine Inc.) – UT Health Science Center-Houston
  18. Dr. Jim Song (Tranquility Biodesign) – Texas A&M-College Station
  19. Dr. Rosa Selenia Guerra-Resendez (Quetzal Bio, LLC) – Rice University
  20. Dr. Cassian Yee (Mongoose Bio, LLC) – UT-MD Anderson Cancer Center
  21. Dr. Manjeet Rao (Niragen, Inc.) – UT Health Science Center-San Antonio


Trending News